Evidence map›Paper›PMID 15323552›Full record

ArticleBiochemistry2004

Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells.

Xin Chen, Li Hui, David A Foster, Charles Michael Drain

Abstract readComparative Study
In one paragraph

Article in Biochemistry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 186 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. IUCrData · 2024
    Article
  5. Article
  6. Heterosubstituted Derivatives of PtPFPP for OBioconjugate chemistry · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xin ChenDepartment of Chemistry and Biochemistry, Hunter College and the Graduate Center of the City University of New York, 695 Park Avenue, New York, New York 10021, USA.
Li Hui
David A Foster
Charles Michael Drain
Hunter College · USRockefeller University · US

Funding

WILD TYPE &MUTANT P53 INTERACTIONS WITH HIV LTR DNAG12RR003037 · NCRR · HUNTER COLLEGE · PI DOTTIN, ROBERT P · 1985 to 2011
$27.6M
UBIQUITINATED PROTEIN DEGRADATION AND NEURODEGENERATIONS06GM060654 · NIGMS · HUNTER COLLEGE · PI LUINE, VICTORIA N · 2000 to 2011
$21.2M
Role of phospholipase D in tumorigenesisR01CA046677 · NCI · HUNTER COLLEGE · PI FOSTER, DAVID A · 1997 to 2014
$3.6M
BASIS FOR TRANSFORMATION BY FUJINAMI SARCOMA VIRUSR29CA046677 · NCI · HUNTER COLLEGE · PI FOSTER, DAVID A · 1989 to 1993
–
NCI NIH HHS CA46677NCI NIH HHS R01 CA046677NCRR NIH HHS G12 RR003037NCRR NIH HHS RR-03037NIGMS NIH HHS GM60654NIGMS NIH HHS S06 GM060654
6 · The paper itself

Abstract

Since the role of saccharides in cell recognition, metabolism, and cell labeling is well-established, the conjugation of saccharides to drugs is an active area of research. Thus, one goal in the use of saccharide-drug conjugates is to impart a greater specificity toward a given cell type or other targets. Although widely used to treat some cancers and age related macular degeneration, the drugs used in photodynamic therapy (PDT) display poor chemical selectivity toward the intended targets, and uptake by cells most likely arises from passive, diffusional processes. Instead, the specific irradiation of the target tissues, and the formation of the toxic species in situ, are the primary factors that modulate the selectivity in the present mode of PDT. We report herein a two-step method to make nonhydrolyzable saccharide-porphyrin conjugates in high yields using a tetra(pentafluorophenyl)porphyrin and the thio derivative of the sugar. As a demonstration of their properties, the selective uptake (and/or binding) of these compounds to several cancer cell types was examined, followed by an investigation of their photodynamic properties. As expected, different malignant cell types take up one type of saccharide-porphyrin conjugate preferentially over others; for example, human breast cancer cells (MDA-MB-231) absorb a tetraglucose-porphyrin conjugate over the corresponding galactose derivative. Doseametric studies reveal that these saccharide-porphyrin conjugates exhibit varying PDT responses depending on drug concentration and irradiation energy. (1) Using 20 microM conjugate and greater irradiation energy induces cell death by necrosis. (2) When 10-20 microM conjugate and less irradiation energy are used, both necrosis and apoptosis are observed. (3) Using 10 microM and the least irradiation energy, a significant reduction in cell migration is observed, which indicates a reduction in aggressiveness of the cancer cells.

Indexed as

Drug Delivery SystemsAnimalsApoptosisBinding SitesBreast NeoplasmsCell Line, TransformedCell Line, TumorCell MovementCell SurvivalCSK Tyrosine-Protein KinaseFibroblastsGlycosylationHumansOncogene Protein pp60(v-src)PhotochemotherapyPoly(ADP-ribose) Polymerases5,10,15,20-tetrakis(4-methoxyphenyl)porphyrinCSK protein, humanCSK Tyrosine-Protein KinaseOncogene Protein pp60(v-src)Poly(ADP-ribose) PolymerasesPorphyrinsProtein-Tyrosine Kinasessrc-Family KinasesThioglycosides

Identifiers

PMID15323552
PMCPMC6180334
OpenAlexW2012483297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.